简介:大麻二酚(CBD),一种不令人陶醉的大麻素,可能参与骨骼重塑,但是人类研究是有限的。在这个系列中,我们探讨了口服CBD对骨转换的影响。材料和方法:两名绝经后骨量减少的妇女(T评分=-1至-2.5)随机接受每日100或300mgCBD(口服,bisindie[twiceperday])for12weeks.骨吸收(羧基末端胶原交联[CTx])和骨形成(1型前胶原N端前肽[P1NP],骨特异性碱性磷酸酶[BSAP],和骨钙蛋白[OC]);安全措施;CBD和代谢物的血浆浓度;睡眠障碍;抑郁症状,焦虑,和压力;和生活质量,被评估。结果:CBD耐受性良好,生命体征没有临床意义的变化,血液学,化学,或尿液分析,无不良事件报告。减少(%变化与基线)在CTx中(-8.5%,-28.1%),P1NP(-9.9%,-39.5%),BSAP(-12.7%,-74.8%),和OC(-16.0%,-6.7%)在每天口服100或300mgCBD12周后观察到,分别。两名参与者自我报告消耗了95.3%和98.8%的CBD剂量,分别。CBD和选择的代谢物在CBD治疗4周和12周后在血浆中可测量。睡眠障碍没有明显变化,抑郁症,焦虑,压力,或观察生活质量。结论:每天两次口服给药12周后,CBD的耐受性良好,并且与测得的骨转换标志物的减少有关。对CBD治疗的依从性很好。有必要对CBD在绝经后妇女中的骨保护作用进行大规模随机临床试验。
Introduction: Cannabidiol (CBD), a nonintoxicating cannabinoid, may be involved in bone remodeling, but human studies are limited. In this
case series, we explored the effects of oral CBD administration on bone turnover. Materials and Methods: Two postmenopausal women with osteopenia (T-score=-1 to -2.5) were randomized to receive 100 or 300 mg CBD daily (oral, bis in die [twice per day]) for 12 weeks. Serum markers of bone resorption (carboxyl-terminal collagen crosslinks [CTx]) and bone formation (procollagen type 1 N-terminal propeptide [P1NP], bone-specific alkaline phosphatase [BSAP], and osteocalcin [OC]); safety measures; plasma concentrations of CBD and metabolites; sleep disturbance; symptoms of depression, anxiety, and stress; and quality of life, were assessed. Results: CBD was well tolerated, with no clinically significant change in vital signs, hematology, chemistry, or urinalysis, and no adverse events reported. Reductions (% change vs. baseline) in CTx (-8.5%, -28.1%), P1NP (-9.9%, -39.5%), BSAP (-12.7%, -74.8%), and OC (-16.0%, -6.7%) were observed after 12 weeks of oral administration of 100 or 300 mg CBD daily, respectively. The two participants self-reported consuming 95.3% and 98.8% of CBD doses, respectively. CBD and select metabolites were measurable in plasma after 4 and 12 weeks of CBD treatment. No notable changes in sleep disturbance, depression, anxiety, stress, or quality of life were observed. Conclusions: CBD was well tolerated after 12 weeks of twice-daily oral administration and was associated with reduction in measured markers of bone turnover. Compliance with CBD treatment was good. Large-scale randomized clinical trials into the bone protective effects of CBD in postmenopausal women are warranted.